Market Cap 495.01M
Revenue (ttm) 0.00
Net Income (ttm) -49.77M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 594,000
Avg Vol 1,145,738
Day's Range N/A - N/A
Shares Out 31.29M
Stochastic %K 10%
Beta 0.50
Analysts Strong Sell
Price Target $53.00

Company Profile

LENZ Therapeutics, Inc. operates as a biopharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, Cal...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 925 7000
Address:
201 Lomas Santa Fe Drive, Suite 300, Solana Beach, United States
Max_Regards
Max_Regards Feb. 3 at 5:23 PM
$LENZ another day of speculation and surfing the Red Sea. Still far too early to declare a winner in this market. Still far too early to declare the market even exists and consumers want the product from any company. Don’t let short term volatility and emotion affect long term strategies.
1 · Reply
LUCKYbug
LUCKYbug Feb. 3 at 4:08 PM
1 · Reply
philipv777
philipv777 Feb. 2 at 3:52 PM
$LENZ https://cdn.prod.website-files.com/64b01a75c3f993c7c15191dd/677ff7ffefa72f00cca150c7_PR%20Tenpoint%20Announces%20Positive%20Topline%20Clinical%20Data_8Jan2025_1pm.pdf https://ir.lenz-tx.com/news-events/press-releases/detail/11/lenz-therapeutics-announces-positive-topline-data-from-phase-3-clarity-presbyopia-trials Compare the two press releases. Which data set is clearer? Theoretical benefit is helpful when vying for expert buy-in, but it is not clear to me from the provided evidence that brimochol is better for presbyopia; hopefully they'll publish in a peer reviewed journal soon. Ultimately the market will decide what works best.
1 · Reply
BryGuy29
BryGuy29 Feb. 1 at 4:22 AM
$LENZ yuvezzi with lower risk of retinal complications due to addition of brimonidine combined. This will be massive selling point for yuvezzi over vizz.
5 · Reply
Dreamit2
Dreamit2 Jan. 31 at 6:51 PM
$LENZ If in the next 3 to 5 years Vizz has sales of 500 million at let's say 35% profit margin, that's a 175 million profit, divided by 31 million shares outstanding gives the company 5.64 cents a share × a price earnings of about 15 gives us around $85 a share. And I think that's pretty conservative.
2 · Reply
UgoGreg
UgoGreg Jan. 31 at 4:45 PM
$LENZ https://youtu.be/tAh290QykVA
1 · Reply
No_Body_Knows
No_Body_Knows Jan. 30 at 5:20 PM
2 · Reply
HypnoTrader
HypnoTrader Jan. 29 at 8:00 PM
$LENZ when you put Sarah Jessica Parker on TV, suddenly blurry vision becomes a blessing in disguise.
3 · Reply
tdil
tdil Jan. 29 at 7:25 PM
$LENZ What is going on?
1 · Reply
Max_Regards
Max_Regards Jan. 29 at 3:34 PM
$LENZ okay this makes sense, VIZZ was first to market with the new round of presbyopia eye drop treatments. We now have other companies getting ready for commercial release. This is both good and bad, will we have the market to ourselves? No, but other companies wouldn’t invest hundreds of millions in developing these drops if they didn’t think the market for it was there and willing to use the product. Tenpoint Therapeutics Ltd: Announced FDA approval on January 28, 2026, for YUVEZZI (carbachol and brimonidine tartrate), described as the first dual-agent eye drop for presbyopia. Note: Tenpoint has engaged in significant financing and was reported to be preparing for a commercial launch in Q2 2026. Only thing we can do is wait and see how volume looks for us vs competitors. Challenge being many competitors are not publicly traded companies so their information won’t be as widely available.
5 · Reply
Latest News on LENZ
LENZ Therapeutics: Was That A Market Overreaction?

Dec 17, 2025, 9:02 AM EST - 6 weeks ago

LENZ Therapeutics: Was That A Market Overreaction?


LENZ Therapeutics to Present at Upcoming Investor Conferences

Nov 25, 2025, 4:05 PM EST - 2 months ago

LENZ Therapeutics to Present at Upcoming Investor Conferences


LENZ Therapeutics, Inc. (LENZ) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 1:21 PM EST - 3 months ago

LENZ Therapeutics, Inc. (LENZ) Q3 2025 Earnings Call Transcript


LENZ Therapeutics: Undervalued Ahead Of PDUFA

Jul 29, 2025, 1:32 PM EDT - 6 months ago

LENZ Therapeutics: Undervalued Ahead Of PDUFA


LENZ Therapeutics: Presbyopia Eyedrops Look Promising

Jul 1, 2025, 4:23 PM EDT - 7 months ago

LENZ Therapeutics: Presbyopia Eyedrops Look Promising


LENZ Therapeutics, Inc. (LENZ) Q1 2025 Earnings Call Transcript

May 9, 2025, 10:33 AM EDT - 9 months ago

LENZ Therapeutics, Inc. (LENZ) Q1 2025 Earnings Call Transcript


LENZ Therapeutics: Freedom From Reading Glasses

Apr 7, 2025, 8:00 AM EDT - 10 months ago

LENZ Therapeutics: Freedom From Reading Glasses


LENZ Therapeutics Stock Is Attractive Before PDUFA

Mar 27, 2025, 5:33 PM EDT - 11 months ago

LENZ Therapeutics Stock Is Attractive Before PDUFA


LENZ Therapeutics, Inc. (LENZ) Q4 2024 Earnings Call Transcript

Mar 19, 2025, 8:09 PM EDT - 11 months ago

LENZ Therapeutics, Inc. (LENZ) Q4 2024 Earnings Call Transcript


LENZ Therapeutics to Host Commercial Day on April 15, 2025

Mar 3, 2025, 8:00 AM EST - 1 year ago

LENZ Therapeutics to Host Commercial Day on April 15, 2025


Lucy Therapeutics Appoints Kim Drapkin as Board Chair

Oct 15, 2024, 8:00 AM EDT - 1 year ago

Lucy Therapeutics Appoints Kim Drapkin as Board Chair

ABOS


LENZ Therapeutics: Upcoming PDUFA, Strong Data, Some Risks

Aug 30, 2024, 8:00 AM EDT - 1 year ago

LENZ Therapeutics: Upcoming PDUFA, Strong Data, Some Risks


Max_Regards
Max_Regards Feb. 3 at 5:23 PM
$LENZ another day of speculation and surfing the Red Sea. Still far too early to declare a winner in this market. Still far too early to declare the market even exists and consumers want the product from any company. Don’t let short term volatility and emotion affect long term strategies.
1 · Reply
LUCKYbug
LUCKYbug Feb. 3 at 4:08 PM
1 · Reply
philipv777
philipv777 Feb. 2 at 3:52 PM
$LENZ https://cdn.prod.website-files.com/64b01a75c3f993c7c15191dd/677ff7ffefa72f00cca150c7_PR%20Tenpoint%20Announces%20Positive%20Topline%20Clinical%20Data_8Jan2025_1pm.pdf https://ir.lenz-tx.com/news-events/press-releases/detail/11/lenz-therapeutics-announces-positive-topline-data-from-phase-3-clarity-presbyopia-trials Compare the two press releases. Which data set is clearer? Theoretical benefit is helpful when vying for expert buy-in, but it is not clear to me from the provided evidence that brimochol is better for presbyopia; hopefully they'll publish in a peer reviewed journal soon. Ultimately the market will decide what works best.
1 · Reply
BryGuy29
BryGuy29 Feb. 1 at 4:22 AM
$LENZ yuvezzi with lower risk of retinal complications due to addition of brimonidine combined. This will be massive selling point for yuvezzi over vizz.
5 · Reply
Dreamit2
Dreamit2 Jan. 31 at 6:51 PM
$LENZ If in the next 3 to 5 years Vizz has sales of 500 million at let's say 35% profit margin, that's a 175 million profit, divided by 31 million shares outstanding gives the company 5.64 cents a share × a price earnings of about 15 gives us around $85 a share. And I think that's pretty conservative.
2 · Reply
UgoGreg
UgoGreg Jan. 31 at 4:45 PM
$LENZ https://youtu.be/tAh290QykVA
1 · Reply
No_Body_Knows
No_Body_Knows Jan. 30 at 5:20 PM
2 · Reply
HypnoTrader
HypnoTrader Jan. 29 at 8:00 PM
$LENZ when you put Sarah Jessica Parker on TV, suddenly blurry vision becomes a blessing in disguise.
3 · Reply
tdil
tdil Jan. 29 at 7:25 PM
$LENZ What is going on?
1 · Reply
Max_Regards
Max_Regards Jan. 29 at 3:34 PM
$LENZ okay this makes sense, VIZZ was first to market with the new round of presbyopia eye drop treatments. We now have other companies getting ready for commercial release. This is both good and bad, will we have the market to ourselves? No, but other companies wouldn’t invest hundreds of millions in developing these drops if they didn’t think the market for it was there and willing to use the product. Tenpoint Therapeutics Ltd: Announced FDA approval on January 28, 2026, for YUVEZZI (carbachol and brimonidine tartrate), described as the first dual-agent eye drop for presbyopia. Note: Tenpoint has engaged in significant financing and was reported to be preparing for a commercial launch in Q2 2026. Only thing we can do is wait and see how volume looks for us vs competitors. Challenge being many competitors are not publicly traded companies so their information won’t be as widely available.
5 · Reply
Itinerant
Itinerant Jan. 29 at 3:07 PM
$LENZ Why is this happening? Any theories?
2 · Reply
NYTWben
NYTWben Jan. 29 at 3:04 PM
$LENZ day two fed , everything is red so far this morning. Shorts are back into Lenz but in my opinion the risk reward ratio is very different from a few months ago at these levels and the many catalysts that could hit any day. I have to much of this stock but. Tempted to get more.
0 · Reply
dbears729
dbears729 Jan. 28 at 9:42 PM
$LENZ 42% short interest with 8 days to cover, juiiiicy 🕺🏻🧨 $SPY $GME
1 · Reply
Max_Regards
Max_Regards Jan. 28 at 5:42 PM
$LENZ Shorts have started increasing their position again now that market volatility is down. Up to 26% from 24% a few weeks ago. Hold strong bulls, we’ve got this 💪🏽
1 · Reply
Max_Regards
Max_Regards Jan. 27 at 7:45 PM
$LENZ the battle for $20
1 · Reply
NYTWben
NYTWben Jan. 27 at 5:40 PM
$LENZ $LENZ Hi everyone, I’m on Day 3 of using VIZZ and wanted to share my experience. For context, I’m a 46-year-old male with moderate presbyopia. I received my VIZZ samples after my annual eye exam, where my eye doctor ruled out retinal risk factors. Each morning when I apply the drops, I feel a mild tingling sensation that fades within about eight minutes. The results have been impressive. Both my near and distance vision feel noticeably sharper. I spend a large part of my day on my phone and reading documents, and I am no longer pushing things farther away to find the point where text comes into focus. That alone has been a meaningful quality-of-life improvement. I did not notice any dimming effect (probably not an issue in bright Miami), and the drops effect last about ten hours for me. Overall, I am very impressed with VIZZ. After just a few days, I can already see myself using these drops on most workdays and am already thinking about not going back to glasses.
4 · Reply
Max_Regards
Max_Regards Jan. 27 at 4:06 AM
$LENZ SJP has a link to the VIZZ find a doctor website. 10 million followers. Nice 👍🏻
0 · Reply
Max_Regards
Max_Regards Jan. 27 at 2:26 AM
$LENZ held the $20 floor nicely today 💪🏽
0 · Reply
SirRahal
SirRahal Jan. 26 at 3:14 PM
$LENZ I think I might put my Stop Loss at $19 and not look at this for a couple of months.
0 · Reply
Max_Regards
Max_Regards Jan. 26 at 2:18 PM
$LENZ here’s to hopefully another week of buying pressure. When searching my area on VIZZ to see what docs have samples. They went from 2/10 to 10/10 Awareness to eye care professionals I’d call a great success. Now we wait to see the lagging effect of the direct consumer Sarah Jessica Parker campaign. Commercial seems generic but gets the point accomplished and across and it’s very relatable.
0 · Reply
kindness123
kindness123 Jan. 25 at 2:53 PM
$LENZ 😅
2 · Reply
BillionerOfKing
BillionerOfKing Jan. 24 at 11:13 PM
$LENZ Current Stock Price: $20.51 Contracts to trade: $20 LENZ Feb 20 2026 Call Entry: $1.30 Exit: $2.22 ROI: 70% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply